Dr. Abhijit Datta brings over 20 years of medical device/IVD product development and commercialization experience to Truvian’s Scientific Advisory Board. Dr. Datta currently serves as Vice President of Operations and a member of the executive management team at Diazyme Laboratories. Dr. Datta is actively involved in product development and has experience with phase transition of health care products through regulatory cycles and scale up manufacturing in compliance with FDA, Health Canada, NMPA and EU: CE IVD, USDA, DEA and various local and state regulatory authorities.
Dr. Datta was an American Cancer Society Post-Doctoral Fellow at the Dana-Farber Cancer Institute, Harvard University Medical School and the Ludwig Institute of Cancer Research, UCSD, where his work focused on DNA repair, recombination and interactions with cell cycle checkpoint. He received his master’s degree in Biosciences and Biotechnology from IIT Roorkee, India, and a Biochemistry and Molecular Biology Ph.D. from Emory University where his thesis focused on DNA recombination. Dr. Datta is an author on fifteen scientific publications and inventor on nine granted patents. Dr. Datta served on board of Diazyme Shanghai, a life science company and serves as an advisor to biotech companies.